To present findings on the efficacy of NSAIDs in treating Ghosal hematodiaphyseal dysplasia (GHD) and to explore the impact of different donor types in allogeneic transplant for severe aplastic anemia.
Key Findings:
All patients with GHD achieved hemoglobin and platelet responses after NSAID treatment.
NSAIDs demonstrated complete efficacy with minimal iatrogenic effects compared to corticosteroids.
GHD should be considered in patients with predominant anemia and specific radiological findings.
The comparative study revealed significant differences in outcomes based on donor types, which need further exploration.
Interpretation:
NSAIDs are a promising first-line treatment for GHD, offering effective management with fewer complications than traditional steroid therapies.
Limitations:
Small sample size for GHD treatment study, limiting generalizability.
Lack of long-term follow-up data on donor type impact in aplastic anemia, which may affect treatment decisions.
Conclusion:
NSAIDs provide an effective alternative treatment for GHD, warranting consideration in clinical practice for inherited bone marrow failure syndromes, particularly in light of their favorable safety profile.
